Dulaglutide Market Report 2026

Dulaglutide Market Overview

• Dulaglutide market size has reached to $4.47 billion in 2025 • Expected to grow to $6.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: The Rising Prevalence Of Type 2 Diabetes Fuels Growth In The Dulaglutide Market • Market Trend: Glenmark's Launch Of Lirafit Biosimilar Expands Access To Anti-Diabetic Treatments • North America was the largest region in 2025.

What Is Covered Under Dulaglutide Market?

Dulaglutide is a medication used to manage blood sugar levels in individuals with type 2 diabetes. It is a type of glucagon-like peptide-1 (GLP-1) receptor agonist, which works by mimicking the action of the natural hormone GLP-1. Dulaglutide is administered via subcutaneous injection, typically once a week. The main types of dulaglutide are syringe pens and multi-dose bottles. A syringe pen is a device designed for injecting medications like dulaglutide. It combines the medication and a needle in one compact, easy-to-use tool. Patients can adjust the dosage, making it convenient for those who need precise amounts. The various applications include medical insurance, pharmaceutical, and clinical research and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Dulaglutide Market Growth Forecast?

The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $6.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to obesity-diabetes overlap treatment, long-acting formulation innovation, biosimilar development, digital diabetes management tools, emerging market access. Major trends in the forecast period include rising adoption of glp-1 receptor agonists, growing preference for once-weekly injectable therapies, expansion of diabetes combination treatment approaches, increasing use in cardiometabolic risk management, growth of patient adherence support programs.

Global Dulaglutide Market Segmentation

1) By Type: Syringe Pen, Multi-Dose Bottles 2) By Application: Medical Insurance, Pharmaceutical, Clinical Research 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Syringe Pen: Disposable Syringe Pen, Reusable Syringe Pen 2) By Multi-Dose Bottles: Single-Dose Bottles, Multi-Dose Vials

What Is The Driver Of The Dulaglutide Market?

The increasing prevalence of type 2 diabetes is expected to propel the growth of the dulaglutide market going forward. Type 2 diabetes is a chronic condition where the body becomes resistant to insulin or doesn't produce enough insulin, leading to elevated blood sugar levels. The increase in type 2 diabetes is due to rising rates of obesity, poor diets, and sedentary lifestyles. Dulaglutide helps manage type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in response to food intake, which lowers blood sugar levels. For instance, in April 2023, according to a report published by The British Diabetic Association, a UK-based diabetes charity, in the UK, 4.3 million individuals have diabetes and over 2.4 million people in the UK are at high risk of acquiring type 2 diabetes, and registration numbers for 2021–22 are up 148,951. Therefore, the increasing prevalence of type 2 diabetes is driving the growth of the dulaglutide industry.

Key Players In The Global Dulaglutide Market

Major companies operating in the dulaglutide market are Merck And Co. Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Cipla Limited, Intas Pharmaceuticals Limited, Biocon Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Insulet Corporation, Nicholas Piramal India Limited, IPCA Laboratories Limited, Alembic Pharmaceuticals Limited, Ypsomed Holding AG, Wockhardt Limited, MannKind Corporation, Bioton S.A., Midas Pharma GmbH, Senova Technology Co. Ltd., Enomark

Global Dulaglutide Market Trends and Insights

Major companies operating in the dulaglutide market are focused on developing innovative products, such as anti-diabetic drugs, to meet the increasing demand for effective treatments for managing diabetes mellitus. Anti-diabetic drugs are medications that manage and treat diabetes mellitus by regulating blood sugar levels through mechanisms like increasing insulin sensitivity, stimulating insulin production, or slowing glucose absorption from the digestive tract. For instance, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched the first biosimilar of the anti-diabetic drug Liraglutide in India under the brand name Lirafit. This move signifies Glenmark's strategic entry into the biosimilar market for anti-diabetic drugs, aimed at providing patients with a more affordable treatment option. The biosimilar is expected to maintain efficacy and safety profiles comparable to the original drug, meeting stringent regulatory standards.

What Are Latest Mergers And Acquisitions In The Dulaglutide Market?

In August 2023, Lupin Limited, an Indian-based pharmaceutical company, acquired two diabetic brands from Boehringer Ingelheim for €26 million ($28 million). With this acquisition, Lupin aims to strengthen its position in the diabetes care market by enhancing its product portfolio and market presence in diabetes management. Boehringer Ingelheim is a Germany-based company involved in developing and marketing dulaglutide, a medication used to treat type 2 diabetes.

Regional Outlook

North America was the largest region in the dulaglutide market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dulaglutide Market?

The dulaglutide market consists of sales of blood glucose monitors, needles, and injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dulaglutide Market Report 2026?

The dulaglutide market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dulaglutide industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.